Articles related to RESEARCH & CLINICAL TRIALS

Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.

A longitudinal study demonstrates that early peanut introduction can reduce allergy risk by 81%, with protection persisting through early adolescence despite varying consumption patterns.

Recent clinical trials demonstrate significant advances in targeted therapies for NETs, with 177Lu-Dotatate showing particular promise as a first-line treatment option for higher-grade GEP-NETs.

Advanced molecular screening methods for colorectal cancer and AI-assisted colonoscopy detection systems represent significant developments in diagnostic technology, potentially improving both accuracy and accessibility of cancer screening programs.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.